Novel antidotes for target specific oral anticoagulants

  • Exp Hematol Oncol. 2015 Sep 15;4:25. doi: 10.1186/s40164-015-0020-3.
Arundhati Das  1 ,  Delong Liu  2
Affiliations
  • 1. Department of Medicine, New York Medical College and Westchester Medical Center, Valhalla, NY 10595 USA.
  • 2. Department of Medicine, New York Medical College and Westchester Medical Center, Valhalla, NY 10595 USA ; Henan Cancer Hospital and the Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, China.
PMID: 26380149 DOI: 10.1186/s40164-015-0020-3
Abstract

Target specific oral anticoagulants (dabigatran, rivaroxaban, apixaban, and edoxaban) are changing the landscape of anticoagulation. The major drawback is the absence of an effective antidote for severe bleedings and/or prior to procedures. Currently there are a few promising antidotes undergoing clinical trials. This review summarized the latest development in idarucizumab, andexanet alpha and PER977.

Products